Anecdotal reports have suggested that transplantation of hepatitis C virus (HCV) antibody positive (Ab+)/nucleic acid test negative (NAT−) donor kidneys into HCV negative recipients is not associated with HCV transmission. We reviewed our center's outcomes of 32 HCV negative patients who received kidney allografts from 25 donors who were HCV Ab+/NAT−. The mean recipient age was 56.9 ± 12.1 years and the mean donor age was 41.5 ± 14 years, with a median Kidney Donor Profile Index (KDPI) of 68%. Twelve donors (48%) met Public Health Service (PHS) increased risk status. All patients received antithymocyte globulin induction followed by tacrolimus, mycophenolate mofetil, and steroid maintenance immunosuppression. With a mean follow-up posttransplant of 10 ± 2.7 months, 1-and 3-month serum creatinine levels were 1.7 ± 0.8 and 1.3 ± 0.4, respectively, and patient and graft survival rates were 100% and 97%, respectively. Fourteen patients (44%) seroconverted and became HCV Ab+ posttransplant. However, all 32 patients were HCV RNA negative at 1-and 3-months posttransplant, and 27 and 8 patients tested at 6-and 12-months posttransplant, respectively, remain HCV RNA negative. In conclusion, transplantation of HCV Ab+/NAT− kidneys to HCV negative recipients frequently causes HCV Ab seroconversion but not HCV viremia.
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| INTRODUC TI ON
Although there was a record number of deceased organ donors (10 281) in 2017 (https://unos.org), the gap between the number of kidney transplantations performed and the number of patients on the waiting list remains substantial. One way of increasing the donor pool is to utilize more organs from hepatitis C virus (HCV) positive donors. HCV nucleic acid testing (NAT) for all organ donors began in August 2015;
prior to this, donor HCV status was based solely on serologic testing.
The importance of distinguishing between HCV NAT+ (viremic) versus HCV antibody (Ab)+/NAT− (nonviremic) donors has been recognized, and there has been a call to redefine the definition of an "HCV positive 
| PATIENTS AND ME THODS

| Posttransplant HCV monitoring
All patients were HCV antibody negative prior to transplant; none had a history of HCV infection in the past. Posttransplant, HCV Ab, and HCV ribonucleic acid (RNA) status were checked at the 1-, 3-, 6-, and 12-month time points. In patients whose donors were PHS increased risk, HBV and HIV testing were also done at the same time points.
| Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics. Values are reported as mean ± standard deviation (SD) or as median.
Continuous variables were compared using Student's t test and categorical variables with the chi-square test, with P < .05 considered as statistically significant.
| RE SULTS
Of 217 kidney transplants performed at Loma Linda University
Medical Center (LLUMC) during the study period, 36 patients received organs from HCV RNA+ and/or HCV Ab+ donors. Four HCV NAT+ patients were transplanted kidneys from HCV NAT+ donors and are excluded from this analysis. Thirty-two patients with a mean age of 56.9 ± 12.1 years received kidneys from 25 HCV Ab+/NAT− donors and comprise the study group (Table 1 ). The median time on hemodialysis prior to transplant in these patients was 7.4 years compared to 6.7 years for the entire cohort (P = .5), excluding pediatric, living donor, and multi-organ recipients. The mean donor age was 41.5 ± 14 years, with a median KDPI of 68% (interquartile range [IQR] 51-87%) ( Table 1 ). In 7 cases, both kidneys were transplanted from the same donor. The majority of the organs were imports; only one donor kidney originated from our own organ procurement organization (OPO). The median cold ischemia time (CIT) was 1410 minutes; 6 were donation after cardiac death (DCD) donors.
TA B L E 1 Donor and recipient characteristics
The mean follow-up posttransplant was 10.0 ± 2.7 months.
Fifteen patients (47%) had delayed graft function (DGF) and one patient had primary nonfunction (PNF). One-month and 3-month serum creatinine levels were 1.7 ± 0.8 and 1.3 ± 0.4, respectively, and patient and graft survival were 100% and 97%, respectively.
There was one episode of biopsy-proven rejection; patient 31 had acute antibody-mediated rejection (AMR) treated with a course of steroid pulse, IVIg, rituximab, and plasma exchange. (Table 2 ).
| Donor characteristics and HCV outcomes
All 32 recipients were HCV RNA negative at 1-and 3-months posttransplant ( Table 2) . Twenty-seven patients have been tested Table 2 ).
| D ISCUSS I ON
In this study, we demonstrate that transplantation of HCV Ab+/ NAT− kidneys to HCV negative recipients with up to 12 months of follow-up frequently results in HCV seroconversion but not viremia, suggesting the absence of HCV transmission. All 32 patients who received kidneys from 25 donors were HCV RNA negative at 1-and 3-months posttransplant, and 27 and 8 patients tested at 6-and 12-months posttransplant, respectively, have all remained HCV RNA negative (Table 2) . Fourteen (44%) of the recipients became HCV Ab+, and the reason for the seroconversion and why it occurred only in a subset of patients is unclear. We found no apparent factors predictive of seroconversion, although our study cohort was small. There was no difference in immunosuppression between patients who did and did not seroconvert, ; PHS-increased risk donors from our study had serologic and NAT testing performed from 0-6 days after admission (median 4 days). HCV transmission risk rates from PHS-increased risk donors have been estimated to be from <0.01% to 0.32% depending on the donor risk factor (highest for IVDU), 7 translating to approximately 1-3 proven or probable donor HCV transmission events per year according to DTAC data. Twelve (48%) of the donors had PHS-increased risk status (Table 1) , and it is possible that the number of drug-related deaths was even higher. No transmission of HIV or HBV infection occurred in our patients.
At our center, the use of HCV Ab+/NAT− donor kidneys is discussed with kidney transplant candidates during the initial evaluation, at subsequent pretransplant visits, and again at the time of the offer.
Patients are told that there is a possibility of false-positive serologic testing but more than likely, these donors had had HCV infection and either cleared the infection spontaneously or with treatment, and that there has been no reported transmission of HCV infection from these nonviremic donors after kidney transplantation. 1, [3] [4] [5] Informed consent is obtained prior to the transplant with full disclosure of donor information to the recipient, especially the social history and drug use.
The majority of our patients have agreed to accept these organs and proceed with the transplant, particularly when notified that we have had no HCV transmission in the use of these organs and given the relative risk of wait list mortality associated with the long wait times in our donor service area (median time on dialysis for the patients in this study: 7.4 years, range 1.6-11.1 years). For those receiving their kidney from a PHS-increased risk donor, patients are notified of disease transmission risk rates of HCV infection as noted above.
Our clinical experience shows that HCV Ab+/NAT− donor kidneys are generally of good quality. The average KDPI of these donors was 68%; 7 (28%) donors had a KDPI >85%. Sibulesky recently suggested that HCV Ab+/NAT− donor kidneys may be of better quality compared to HCV-negative donor kidneys with a similar KDPI. 19 Longer term outcomes will be required to determine the validity of this hypothesis but our preliminary observation from this study is that HCV+ donors may not warrant an increase in the KDPI of approximately 20% as calculated in the current KDPI determination. 
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